Acting Administrator Andy Slavitt says the Fraud Prevention System has yielded a 10-to-1 return for taxpayers
An investment to fight Medicare fraud is more than paying for itself, CMS Acting Administrator Andy Slavitt announced today. The agency’s Fraud Prevention System has identified $820 million in improper payments in its first 3 years, including $454 million just in calendar year 2014, Slavitt said.
“Very few investments have a 10-to-1 return on taxpayer money,” Slavitt said. “We are proving that in a modern healthcare system you can both fight fraud and avoid creating hassles for the vast majority of physicians who simply want to get paid for services rendered.”
Good data is the key, he said. The availability of the data needed to combat fraud was made possible by the 2010 Small Business Jobs Act, and CMS has also gained tools through the Affordable Care Act. In addition to the Fraud Prevention System, the HHS and the Department of Justice has gone after individual doctors and nurses in a recent crackdown involving 46 individuals and $712 million in false billings.
Having good data reveals patterns of improper practices and allows Medicare to move quickly against providers, making referrals to law enforcement when appropriate. In its third year, the Fraud Prevention System is now creating “high yield” prevention activity, allowing CMS to move beyond the “pay and chase” model, according to Dr Shantanu Agrawal, CMS’ deputy administrator and director of the Center for Program Integrity.
As the program matures, CMS will continue to tweak its formulas to identify lower levels of improper billing, including some providers who might benefit from education in proper billing practices.
For more information, see the Center for Program Integrity.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More